{"url_path":"/sec/apge/8-k/2026-08-11/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1974640/0001140361-26-032231-index.html","accession_number":"0001140361-26-032231","cik":"0001974640","ticker":"APGE","issuer_name":"Apogee Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1974640/0001140361-26-032231-index.html","primary_entity_key":"0001974640","primary_entity_name":"Apogee Therapeutics, Inc."},"word_count":322,"has_tables":true,"body_markdown":"falseApogee Therapeutics, Inc.0001974640CANASDAQ00019746402026-08-112026-08-11\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 8-K\n\nCURRENT REPORT\n\nPURSUANT TO SECTION 13 OR 15(d) OF\n\nTHE SECURITIES EXCHANGE ACT OF 1934\n\nDate of Report (Date of Earliest Event Reported): August 11, 2026\n\nAPOGEE THERAPEUTICS, INC.\n\n(Exact Name Of Registrant As Specified In Its Charter)\n\nDelaware\n\n001-41740\n\n93-4958665\n\n(State or other jurisdiction\n\nof incorporation)\n\n(Commission\n\nFile Number)\n\n(I.R.S. Employer\n\nIdentification No.)\n\nOne Letterman Drive, Building B, Suites B6-850 and B6-800\n\nThe Presidio of San Francisco,\nSan Francisco, California\n\n(Address of principal executive offices)\n\n94129-1492\n\n(Zip Code)\n\nRegistrant’s telephone number, including area code: (650)\n394-5230\n\n221 Crescent St., Building 17, Suite 102b, Waltham, MA 02453\n\nFormer Name or Former address, if changed since last report\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following\nprovisions:\n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))\n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of Each Class\n\n \n\nTicket\n\nSymbol(s)\n\n \n\nName of Exchange\n\non Which Registered\n\nCommon Stock, par value $0.00001 per share\n\n \n\nAPGE\n\n \n\nThe Nasdaq Global Market\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2\nof the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\nEmerging Growth Company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised\nfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}